Avacta Announces Completion of the Sale of Coris Bioconcept SRL
LONDON AND PHILADELPHIA - September 1, 2025 - Further to the announcement on July 28, 2025, Avacta Group plc (AIM: AVCT) a life sciences company developing innovative, targeted oncology drugs, today announces that all closing conditions to the sale of the entire issued share capital of Coris Bioconcept SRL to 3B BlackBio Dx Ltd have been satisfied and the completion of the sale took place on Friday August 29, 2025.
-Ends-
For further information from Avacta, please contact:
|
Peel Hunt (Nomad and Joint Broker) James Steel / Chris Golden |
|
|
Panmure Liberum (Joint Broker) Emma Earl / Will Goode / Mark Rogers Zeus (Joint Broker) James Hornigold / George Duxberry Dominic King |
|
|
ICR Healthcare (Europe/UK media and investors) Mary-Jane Elliott / Jessica Hodgson / Stephanie Cuthbert |
|
|
Investor Contact Renee Leck THRUST Strategic Communications |
|
|
Media Contact Carly Scaduto Carly Scaduto Consulting |
About Avacta - www.avacta.com
Avacta Therapeutics is a clinical-stage life sciences company expanding the reach of highly potent cancer therapies with the pre|CISION® platform. pre|CISION® is a proprietary payload delivery system based on a tumor-specific protease (fibroblast activation protein or FAP) that is designed to concentrate highly potent payloads in the tumor microenvironment while sparing normal tissues. Our innovative pipeline consists of pre|CISION® peptide drug conjugates (PDC) or Affimer® drug conjugates (AffDC) that leverage the tumor-specific release mechanism, providing unique benefits over traditional antibody drug conjugates.
About the pre|CISION® Platform
The pre|CISION® platform comprises an anticancer payload conjugated to a proprietary peptide that is a highly specific substrate for fibroblast activation protein (FAP) which is upregulated in most solid tumors compared with healthy tissues. The pre|CISION® platform harnesses this tumor specific protease to cleave pre|CISION® peptide drug conjugates and pre|CISION® antibody/Affimer® drug conjugates in the tumor microenvironment, thus releasing active payload in the tumor and reducing systemic exposure and toxicity, allowing dosing to be optimized to deliver the best outcomes for patients.